PT-141 Dosage and Side Effects: What the Vyleesi Label Actually Says

PT-141 is the one compound in this site's non-board dosage/side-effects coverage with a genuinely different starting point: bremelanotide has an FDA-approved product, Vyleesi, with a real label, a real set dose, and a real numeric adverse-reaction table drawn from the RECONNECT Phase 3 trials — covered in full evidence-review depth here. That real data is also narrower than most "PT-141 dosage" searches assume: it describes one specific product (a pre-filled autoinjector), one specific dose, and one specific population (premenopausal women with HSDD). This article reports Vyleesi's own numbers precisely, then draws the same honest line the evidence review already establishes: none of that label data was generated on, or reviewed for, the compounded, reconstituted PT-141 powder most vendors actually sell.

Vyleesi's actual approved dose

Vyleesi's label sets a specific, numeric dosing regimen — this is real, FDA-reviewed dosing information, not a study-only data point the way this site's other non-board peptide dosage articles have to report:

• •1.75 mg, injected subcutaneously into the abdomen or thigh, using the single-dose, pre-filled autoinjector.
• •Timing: at least 45 minutes before anticipated sexual activity.
• •Frequency cap: no more than one dose within any 24-hour period, and no more than 8 doses per month.
• •Discontinuation guidance: the label directs discontinuing use if the patient hasn't reported improvement after 8 weeks.

That 8-dose-per-month ceiling isn't an arbitrary caution — our evidence review traces it directly to the label's own hyperpigmentation warning: in the Phase 3 trials, 1% of patients dosed up to 8 times a month developed focal hyperpigmentation, and a separate study that pushed dosing to daily use over 8 consecutive days found 38% of patients developed it — the ceiling exists because the risk was measured to rise with dosing frequency, not set as a round number.

Vyleesi's actual adverse-reaction rates

Vyleesi's label reports its Phase 3 trial adverse-reaction rates as a real, placebo-controlled comparison — the kind of table that simply doesn't exist for any of this site's other non-board peptide reviews, because none of them has an approved product behind it:

Nausea is the standout figure, and the label is direct about its severity: it was "the most commonly reported adverse reaction, reported in 40% of VYLEESI-treated patients, requiring anti-emetic therapy in 13% of VYLEESI-treated patients and leading to premature discontinuation from the trials for 8% of VYLEESI-treated patients¹." Four in ten patients on the approved regimen reported it — not a rare footnote.

Focal hyperpigmentation is the label's second major warning, and its own text is explicit that it may not be temporary: "Resolution of the focal hyperpigmentation was not confirmed in all patients after discontinuation of VYLEESI¹." Patients with dark skin were more likely to develop it, per the label.

Transient blood pressure and heart rate changes occur after each dose — "maximal increases of 6 mmHg in systolic blood pressure (SBP) and 3 mmHg in diastolic blood pressure (DBP) that peaked between 2 to 4 hours post dose," with heart rate reduced by up to 5 beats per minute, typically returning to baseline within 12 hours¹. Because of this, Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.

What this means for compounded, reconstituted PT-141

Here is the distinction this article holds onto throughout, and it cuts in two directions at once.

The dose above is Vyleesi's, not a validated compounded-PT-141 dose. Vyleesi ships as a pre-filled, single-dose autoinjector — never reconstituted by the patient. Compounded PT-141 is sterile lyophilized powder in a vial that the buyer reconstitutes themselves with bacteriostatic water before drawing up a dose, an entirely different delivery product with no FDA review of its dose accuracy, sterility, actual concentration, or purity. This article does not recommend, imply, or convert Vyleesi's 1.75 mg autoinjector dose into a schedule for the reconstituted product — there is no validated method for that conversion, and no completed trial has tested it. Our PT-141 reconstitution calculator will do the vial-to-syringe arithmetic on a number you already have, without validating that number against anything.

The safety warnings above are not autoinjector-specific, and there's no reason to expect a compounded version to be exempt from them. Nausea, hyperpigmentation, and the blood pressure/heart rate effect all trace to bremelanotide's own melanocortin-receptor pharmacology — the MC1R-melanocyte link behind hyperpigmentation, in particular, is a property of what the molecule does once it's in the body, not of the specific syringe that delivered it¹. A compounded seller who doesn't disclose nausea rates, hyperpigmentation risk, or the blood-pressure contraindication isn't offering a version of the drug shown to lack those effects — they're omitting warnings the approved product's own label established for the same active ingredient.

The male-use gap applies here too. Our evidence review covers this in depth: Vyleesi's label states directly it is "not indicated for the treatment of HSDD in postmenopausal women or in men." The dosing and safety data above describes the approved product in its approved population — not a general-purpose libido or performance dose, and not a male-use regimen with the same level of trial support behind it.

For a reader deciding where to actually buy compounded PT-141 rather than pursuing a Vyleesi prescription, our PT-141 provider comparison reads pharmacy sourcing and standing price directly off each seller's own site, including which ones disclose Vyleesi's own documented warnings and which don't.

The bottom line

PT-141 is the one compound in this batch where "dosage and side effects" has a real, FDA-set, numeric answer — but only for one specific product (Vyleesi's autoinjector) and one specific population (premenopausal women with HSDD): 1.75 mg subcutaneously, at least 45 minutes before activity, capped at 8 doses a month, with nausea in 40% of patients and a hyperpigmentation risk that may not fully resolve. None of that data was generated on, or reviewed for, the compounded powder-in-a-vial product most PT-141 marketing actually sells, and there's no mechanistic reason to expect that product to be exempt from the same warnings. For the fuller picture — the Phase 3 trial results behind these numbers, and what evidence (or its absence) exists for PT-141 in men — see our PT-141 evidence review and our dedicated Vyleesi/HSDD article. For the same non-recommendation discipline applied to peptides with no approved product at all, see our GHK-Cu side-effects review and our MOTS-c dosage and side-effects review.